Skip to search formSkip to main contentSkip to account menu

GS-9219

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Tanovea® (first named GS-9219, then VDC-1101, generic name: rabacfosadine) is a pro-prodrug or “double” prodrug of PMEG [9-(2… 
Review
2011
Review
2011
Spontaneous cancers are common in the pet dog population with estimated 60% of dogs that live to 10 years of age developing… 
Review
2010
Review
2010
Spontaneous cancers occur commonly in the pet dog population. Indeed, an estimated 60% of dogs that live to 10 years of age will… 
2009
2009
Purpose: To assess, in dogs with naturally occurring non-Hodgkin's lymphoma, pharmacokinetics, safety, and activity of GS-9219, a… 
2008
2008
3290 GS-9219 is a novel nucleoside analogue that was designed based on a double-prodrug approach applied to limit plasma exposure… 
Review
2008
Review
2008
Recently, Gilead Sciences (Foster City, CA, USA) presented a potential cytostatic drug GS-9219. It is a novel lipophilic prodrug… 
2008
2008
Purpose: GS-9219, a novel prodrug of the nucleotide analogue 9-(2-phosphonylmethoxyethyl)guanine (PMEG), was designed as a… 
2007
2007
AACR Annual Meeting-- Apr 14-18, 2007; Los Angeles, CA 5730 Non-Hodgkin's lymphoma (NHL) is a common hematopoietic cancer in… 
2007
2007
Multiple myeloma is an important hematopoietic cancer in humans and pet dogs. While clinical remission can be achieved using…